<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2015-03442-998-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Combining metabolomics and genomics to develop new approaches for diagnosing and understanding bloodstream infections caused by antimicrobial resistan</narrative>
   <narrative xml:lang="SV">Kombination av metabolmik och genomik f&#xF6;r att diagnostisera och f&#xF6;rst&#xE5; blodinfektioner orsakade av antibiotikaresistenta bakterier</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Blodinfektioner (BI) orsakade av bakteriella patogener &#xE4;r ett ledande problem f&#xF6;r sjukv&#xE5;rden v&#xE4;rlden &#xF6;ver och en vanlig orsak till sjukdom och d&#xF6;dlighet &#xE4;ven i l&#xE4;nder med avancerade sjukv&#xE5;rdssystem. Att behandla BI kr&#xE4;ver ofta intensivv&#xE5;rd inkluderande artificiell ventilering och bloddialys p&#xE5; grund av komplikationer s&#xE5;som multipel organsvikt. Den negativa effekten av BI &#xE4;r s&#xE4;rskilt uttalad i l&#xE5;ginkomstl&#xE4;nder d&#xE4;r den l&#xE5;ga kvaliteten p&#xE5; sjukv&#xE5;rden g&#xF6;r att man inte kan hantera kritiskt sjuka patienter och/eller att antalet sjukhus och deras placering inte m&#xF6;ter de demografiska behoven. Dessutom utg&#xF6;r BI i kombination med antimikrobiell resistens (AMR) ett s&#xE4;rskilt sv&#xE5;rt problem. Dessa infektioner utvecklas snabbt, valet av effektiva behandlingar &#xE4;r begr&#xE4;nsat och processen att v&#xE4;lja en l&#xE4;mplig behandling &#xE4;r l&#xE5;ngsam. I fall av multi-AMR , och brist p&#xE5; effektiva antibiotika &#xE4;r ett faktum, kan v&#xE5;rdpersonal m&#xE5;sta bek&#xE4;mpa allvarlig infektion utan funktionella verktyg med endast empiriska terapier. Skr&#xE4;ckscenariot med en &#xE5;terg&#xE5;ng till den pre-antimikrobiella eran &#xE4;r idag en allt mer realistisk framtidsbild, och det finns begr&#xE4;nsade data avseende epidemiologin g&#xE4;llande AMR och BI i l&#xE5;ginkomstl&#xE4;nder. Vidare &#xE4;r befintliga diagnosmetoder f&#xF6;r BI i dagsl&#xE4;get l&#xE5;ngsamma, ineffektiva och tvingar v&#xE5;rdpersonal att administrera empirisk behandlingar som ej &#xE4;r f&#xF6;rdelaktiga f&#xF6;r patienten och kan driva p&#xE5; spridiningen av AMR globalt ytterligare. Med tanke p&#xE5; de akuta globala utmaningar som f&#xF6;rknippas med AMR och BI &#xE4;r syftet med v&#xE5;r studie:  1. Att unders&#xF6;ka b&#xF6;rdan och den kliniska epidemiologin av BI vid ett terti&#xE4;rt sjukhus i Vietnam, ett l&#xE5;g-medel inkomstland med en befolkning p&#xE5; 90,6 miljoner m&#xE4;nniskor. Identifieringen och karakteriseringen av bakterier som orsakar BI kommer att utf&#xF6;ras i samband med AMR (med helgenomsekvensering). P&#xE5;verkan av AMR och typen av infekterande patogener p&#xE5; sjukdomsutfallet kommer att analyseras.  2. Att detektera artspecifika och AMR relaterade metabolitprofiler hos bakterier som orsakar BI. Detta kommer att utf&#xF6;ras i b&#xE5;de blodprover fr&#xE5;n patienter med BI och i bakteriekulturer fr&#xE5;n AMR patogener med distinkt genetisk bakgrund. Metabolomikdata fr&#xE5;n kliniska prover kommer att integreras med motsvarande data fr&#xE5;n genomsekvensering f&#xF6;r att ta fram tillf&#xF6;rlitliga mark&#xF6;rer f&#xF6;r AMR / BI.  3. Att utveckla en  snabb och kostnadseffektiv diagnostisk metod f&#xF6;r AMR/BI baserad p&#xE5; relaterade metabolitsignaturer i torra blodprov. S&#xE5;dana prov kan snabbt transporteras fr&#xE5;n avl&#xE4;gsna landsdelar till st&#xF6;rre v&#xE5;rdcentraler/laboratorier f&#xF6;r analys och v&#xE5;r ambition &#xE4;r att analysera effektiviteten och effekterna av en s&#xE5;dan diagnostisk strategi i l&#xE5;ginkomstomr&#xE5;den i Vietnam. F&#xF6;r att uppn&#xE5; de identifierade m&#xE5;len kommer vi att kombinera spjutspetsmetoder som n&#xE4;sta generations bakteriegenomsekvensering och mycket k&#xE4;nslig metabolitanalys med kliniska data och avancerad bioinformatik. Statistisk signifikans s&#xE4;kras genom rekrytering av 7.000 deltagare till denna studie och v&#xE5;r ambition &#xE4;r att sekvensera 1.000 kliniskt relevanta bakteriegenom. Konsortiet &#xE4;r v&#xE4;l sammansatt f&#xF6;r projektet. Partner Baker har en l&#xE5;ng dokumenterad erfarenhet av mikrobiologiska/kliniska unders&#xF6;kningar i Asien och s&#xF6;kande Antti &#xE4;r ledande inom f&#xE4;ltet g&#xE4;llande metabolomikstudier inom infektionssjukdomar. De s&#xF6;kande har ett etablerat samarbete och har publicerat ihop vilket p&#xE5;visar en god kommunikation och ett effektivt samarbete mellan dessa grupper. Den f&#xF6;rv&#xE4;ntade effekten av studien &#xE4;r av stor betydelse. Inom projektperioden kommer vi att erh&#xE5;lla en detaljerad f&#xF6;rst&#xE5;else av epidemiologi och genomik g&#xE4;llande AMR/BI vid ett stort sjukhus i Vietnam, ett land starkt p&#xE5;verkat av AMR. De viktigaste faktorerna f&#xF6;r spriding av AMR patogener i Vietnam kommer att identifieras med potential att extrapolera resultaten till andra drabbade delar av Asien d&#xE4;r behovet &#xE4;r stort. Den f&#xF6;reslagna strategin f&#xF6;r AMR/BI diagnos via metabolitsignaturer kommer att utvecklas och valideras. En s&#xE5;d</narrative>
   <narrative xml:lang="EN">Bloodstream infections (BSIs) caused by bacterial pathogens are a leading healthcare problem worldwide and a common cause of morbidity and mortality even in the countries with advanced healthcare systems. Treating the BSIs often demands intensive care measures including artificial ventilation and blood dialysis during such complications as multiple organ failure. The negative impact of BSI is especially pronounced in the low-income countries where the quality of the healthcare may be not capable of handling critically ill patients and/or the number of hospitals and their location is disproportional to demographic needs. Additionally, BSIs combined with antimicrobial resistance (AMR) constitute a particularly difficult problem to tackle. The infection develops quickly, the choice of effective therapies is limited and the process of selecting an appropriate treatment is slow as it involves the isolation of the etiologic agent. In case of multi-AMR of the pathogen, and lack of effective antimicrobials, medical professionals may have to fight the severe infection virtually unarmed with only empiric therapies. The grave scenario of returning to the pre-antimicrobial era is looming, and there are limited data regarding the epidemiology of AMR and BSI in low-income countries. Further, diagnostic methods for BSI are currently slow, ineffective and push healthcare personnel to administrate empirical treatment that may be not beneficial for the patient and may drive the AMR globally even further. Considering the urgent global challenges associated with AMR and BSIs, the aims of our study are:  1.To investigate the burden and clinical epidemiology of BSI in a tertiary hospital in Vietnam, a lower-middle income country with a population of 90.6 million. The identification and characterization of the bacteria causing BSI will be performed in the context of AMR (using whole genome sequencing). The influence of AMR and the type of infecting pathogen on the disease outcome will be analyzed.  2.To determine species specific and AMR metabolite signatures of bacteria causing BSIs. This will be performed in both blood samples from subjects with BSI and in bacterial cultures of AMR pathogens with distinct genetic backgrounds. Metabolomics data from clinical samples will be integrated with the corresponding data from genomic sequencing to produce reliable markers of AMR/BSI.  3.To develop a rapid diagnostic approach for the analysis of metabolite signatures of AMR/BSI in dry blood samples. Such samples can be quickly shipped from remote areas to the bigger health centers/laboratories and we aim to analyze the efficiency and the impact of such diagnostic strategy in low-income settings in Vietnam.   To achieve the identified aims we will combine cutting-edge methods as next generation bacterial genome sequencing and highly sensitive metabolite analysis with clinical data and advanced bioinformatics. Statistical significance will be secured through recruiting of 7,000 participants in this study and we aim to sequence 1,000 clinically relevant bacterial genomes. This consortium is established for the project as partner Baker has extensive documented experience of microbiological/clinical investigations in Asian settings and applicant Antti is a field leader in metabolomics studies in infectious diseases. The applicants have a record of joint work and publication indicating successful communication and efficient collaboration of these groups. The expected impact of the study is highly significant. Within the four-year duration of the project we will have a detailed understanding of the epidemiology and genomics of AMR/BSI in a major hospital in Vietnam, a country heavily affected by AMR. The key factors for the propagation of AMR pathogens in Vietnam will be identified with the potential to extrapolate the results to other parts of Asia. The proposed approach for AMR/BSI testing by metabolite signatures will be designed, validated and may potentially d</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Ume&#xE5; universitet</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-01-01" type="2"></activity-date>
  <activity-date iso-date="2019-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">116870.2156255478</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">117000.117000117</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">115069.5019791954</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-11-27"></transaction-date>
   <value currency="USD" value-date="2015-11-27">355901.4390281518</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">116870.2156255478</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">117000.117000117</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">115069.5019791954</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
